Cell Biol Int: Intranscing delivery of SDF-1 alpha pre-treated stem cells improves the re-myelinization of cup multiple sclerosis.

Multiple sclerosis (MS) is an inflammatory and demyelinative disease of the central nervous system (CNS) that can cause disability in middle-age people.
high apoptosis rate and inappropriate nesting are limits in the application of stem cells in cell therapy.
the pre-treatment of bone marrow-filled stem cells (BMSCs) using the substitin cytogenic factor 1 alpha (SDF-1 alpha), also known as C-X-C group degeneration factor 12 (CXCL12), is a method to improve the functional characteristics of cells.
study, which looked at the therapeutic effects of intransifestal delivery of SDF-1 alpha pretreatment BMSCs in mouse models of chronic demyelination induced by cup gession, has been published online in Cell Biol Int.
, culture bMSCs, and pre-treat them with SDF-1 alpha.
then delivered 12 weeks of pre-treated cells to the nose in C57BL/6 mice.
30 days after the cells are delivered.
SDF-1 alpha pre-treatment increases the expression of C-X-C decommoturing factor 4 (CXCR4) on the surface of BMSCs, improves cell survival and reduces in vitro apoptosis.
SDF-1 alpha preprocessing also improves CXCL12 levels in the brain and enhances spatial learning and memory (assessed by Morris Water Maze (MWM), as well as myelinization (evaluated by Luxol Rapid Blue (LFB) and transmission electron microscope (TEM).
In addition, immunofluorescence results showed that the pre-treatment of BMSCs using SDF-1 alpha reduced the protein expression of glial fibroic acidic protein and ionized calcium binding adapter molecules (Iba-1), and increased the expression of less protrusion glial cell line transcription factor-2 (Olig-2) and adenoma e. coli (APC).
, the results show that intranscular delivery of SDF-1 alpha pre-treated BMSCs has some effect on improving the re-myelinization of the multi-sclerosis cup model.
.